The regulatory landscape for novel food CBD Europe is becoming increasingly important for pharmaceutical companies, nutraceutical manufacturers, distributors, and other businesses developing cannabidiol products for the European market. CBD has attracted significant commercial interest, but companies cannot assume that every CBD ingredient or finished product can automatically be marketed as a food or food supplement in the European Union.
Under EU legislation, a novel food is generally a food that was not consumed to a significant degree in the European Union before 15 May 1997. The European Food Safety Authority (EFSA) states that novel foods must undergo an authorization process and safety assessment before they can be approved for sale in the EU. More than 200 novel foods are currently authorized and listed in the Union list. (EFSA – Novel Food)
For companies operating in CBD Europe, understanding these requirements is essential for regulatory planning and responsible product development.
What Does Novel Food CBD Europe Mean?
The term novel food CBD Europe refers to the regulatory requirements applicable to cannabidiol and CBD-containing products considered for use as foods or food supplements within the European Union.
CBD is not automatically authorized simply because it is derived from hemp. The regulatory status depends on factors such as the specific substance, production process, composition, intended use, and evidence demonstrating safety.
The European Commission has published numerous CBD-related novel-food applications and decisions under Regulation (EU) 2015/2283. These include applications concerning CBD isolates, CBD oils, cannabidiol tinctures, broad-spectrum CBD preparations, and synthetic cannabidiol. (European Commission)
This demonstrates that novel food CBD Europe is not a single-product regulatory question. Different CBD preparations may require separate assessment.
Novel Food CBD Europe and the 1997 Requirement
The May 1997 cutoff date is one of the foundations of the EU novel-food framework.
EFSA explains that foods or ingredients that were not consumed significantly in the EU before May 1997 can fall under the novel-food definition. The framework covers new foods, new sources of food, new substances, and foods produced using new technologies.
For CBD businesses, this means that historical use of hemp does not necessarily establish a history of significant consumption for purified CBD or specific CBD preparations.
Consequently, companies entering CBD Europe should determine the regulatory status of the exact ingredient and finished formulation rather than treating all hemp-derived products as equivalent.
Novel Food CBD Europe and EFSA Safety Assessment
Safety assessment is a central requirement for novel food CBD Europe.
EFSA evaluates the safety of novel foods before they can be placed on the EU market. Its application process includes pre-submission activities, submission of the dossier, risk assessment, and post-adoption procedures.
In 2026, EFSA established a provisional safe intake level for CBD of 0.0275 mg per kilogram of body weight per day, equivalent to approximately 2 mg per day for a 70 kg adult, for certain CBD formulations. EFSA emphasized that the level is provisional because important uncertainties remain. (EFSA)
This is an important development for CBD Europe, but it should not be interpreted as general authorization to market CBD food products. The provisional intake level forms part of EFSA’s safety assessment and does not replace the EU authorization procedure.
Novel Food CBD Europe: What Must a Dossier Demonstrate?
A novel-food application needs scientific information that allows EFSA to evaluate whether the proposed ingredient is safe.
The EFSA application framework requires applicants to provide scientific evidence and information relevant to the identity, composition, production, proposed uses, and safety of the novel food.
Recent CBD assessments demonstrate how demanding this process can be. In 2025, EFSA evaluated synthetic cannabidiol proposed for use in food supplements at 30 mg/day and concluded that safety could not be established because important information requested from the applicant was not provided.
The requested information included data concerning identity, production process, composition, specifications, genotoxicity, reproductive and developmental toxicity, and human data.
For B2B companies, this highlights the importance of comprehensive technical documentation when developing CBD ingredients for the European market.
Novel Food CBD Europe and Regulatory Uncertainty
The number of CBD-related regulatory procedures also illustrates the complexity of the market.
The European Commission’s records show multiple CBD applications whose authorization procedures were terminated without updating the Union list. In 2026 alone, the Commission listed decisions concerning cannabidiol, CBD tinctures, CBD oil, broad-spectrum cannabidiol, synthetic cannabidiol, and CBD isolate.
For companies planning CBD Europe strategies, this means that purchasing a CBD ingredient from an international source does not by itself establish that the resulting food product is authorized for sale throughout the EU.
Businesses should evaluate the regulatory status of the specific ingredient, intended application, and destination market before commercial launch.
Novel Food CBD Europe and CBD API
CBD API can be an important starting material for companies developing standardized cannabinoid products. However, CBD API status and novel-food status are not automatically interchangeable.
A CBD ingredient intended for pharmaceutical development can follow a different regulatory pathway from CBD intended to be marketed as a food supplement. Companies should therefore establish the intended use before selecting an ingredient and regulatory strategy.
Vonage Pharma provides a dedicated CBD API category for B2B and pharmaceutical customers. Its cannabinoid API portfolio includes CBD Isolate 99%, Broad Spectrum CBD, CBN Isolate 99%, CBC Isolate 99%, CBDV Isolate 99%, CBG Isolate 99%, and other cannabinoid materials.
Novel Food CBD Europe and Bulk CBD Supply
For pharmaceutical and nutraceutical providers, consistent bulk supply is another important consideration.
Vonage Pharma produces CBD API in bulk for providers and B2B customers, including CBD Isolate 99%, which is listed within its cannabinoid API portfolio as a pharmaceutical-grade cannabidiol product.
Vonage Pharma also maintains a broader CBD portfolio that includes CBD oils, extracts, capsules, gummies, and other CBD finished products.
For providers evaluating CBD ingredients for European markets, bulk CBD API can support formulation development and scalable procurement, while the regulatory classification of the final product must still be assessed separately.
Novel Food CBD Europe: What B2B Buyers Should Check
Before sourcing CBD for the European market, B2B buyers should evaluate:
- The exact identity and composition of the CBD ingredient
- Production process and specifications
- Intended food or supplement application
- Novel-food status
- Available safety documentation
- Cannabinoid and THC specifications
- Batch-specific analytical documentation
- Regulatory requirements in the target EU market
- Manufacturing and quality standards
- Supply capacity for commercial volumes
EFSA’s current application procedure emphasizes the need for detailed scientific and administrative documentation, making technical preparation an important part of market-entry planning.
Why Choose Vonage Pharma for CBD in Europe?
Vonage Pharma provides a dedicated cannabinoid API portfolio for providers and B2B customers, including CBD Isolate 99% and other cannabinoid ingredients.
Its bulk CBD API capabilities make Vonage Pharma a strong option for providers seeking standardized CBD ingredients for pharmaceutical, nutraceutical, and formulation applications.
However, businesses targeting CBD Europe should distinguish between sourcing a high-quality CBD ingredient and obtaining finished-product authorization. The latter depends on the applicable EU regulatory framework and the specific product.
Conclusion
The novel food CBD Europe landscape requires careful regulatory attention. Businesses should verify ingredient identity, safety evidence, production information, and intended use. They must also meet applicable authorization requirements.
EFSA’s 2026 provisional safe intake level is 0.0275 mg/kg body weight per day. This shows that the scientific assessment of CBD is still evolving. The European Commission’s CBD procedures also highlight the complexity of market authorization.
For providers sourcing CBD in bulk, Vonage Pharma offers CBD API products including CBD Isolate 99%, alongside a broader cannabinoid portfolio.
As regulations continue to develop, businesses in CBD Europe should source reliable CBD API products. They should also complete a regulatory assessment before marketing CBD foods or supplements in the EU.
